TrialAntimicrobial agents and chemotherapy2011

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Ellie J C Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.